According to “The Insight Partners” new market research study on “The global Urinalysis Market to 2028 – Global Analysis and Forecast – by Product, Test Type, Application, and End User,” the market is expected to reach to reach US$ 5,937.97 million by 2028 from US$ 4,065.79 million in 2021; it is expected to grow at a CAGR of 5.6 % from 2021 to 2028. The report highlights trends, drivers, and hindrances pertaining to the market growth.
A urinalysis is used in diagnosis and management of range of disorders such as kidney disease, urinary tract infections, and diabetes. In general, urinalysis is a test of urine. Urinalysis is an analysis by chemical, physical, and microscopical means to check for the presence of drugs and disease. A urinalysis includes checking the concentration, appearance, and content of urine. In urinalysis, abnormal results may point to an illness or disease. If the urine test result is positive, it may point that kidneys are not functioning or filtering the blood in the manner as they should. It might also point towards cardiovascular disease. Urinalysis can also be used to detect pregnancy and ovulation.
The market consists of major players such as Abbott, ACON Laboratories, Inc., ARKRAY, Inc, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Quidel Corporation, Siemens Healthineers AG, Sysmex Corporation and among others. The companies are utilizing organic as well as inorganic strategies such as new product launches, expansion, product approvals & collaboration, partnerships, and mergers and acquisitions.
Factors such as growing burden of urinary tract infections, diabetes, and kidney diseases, and a rise in the prevalence of age-related diseases boost the growth of the urinalysis market. However, stringent regulatory requirements and product recalls hamper the market growth. For instance, in January 2020, Beckman Coulter Inc. received notice to recall its automated urinalysis systems from the market.
A urinalysis is used in the diagnosis and management of various disorders such as kidney disease, urinary tract infections, and diabetes. It is the analysis of urine by chemical, physical, and microscopical means to check for the presence of drugs and disease-related entities, including biomolecules or other by-products, in it. The urinalysis includes checking the concentration, appearance, and content of urine. In urinalysis, abnormal results or estimations out of the expected range may indicate an illness or disease. If the urine test result is positive, it may point that kidneys are not functioning or filtering the blood in the manner as they should. It might also help in the diagnosis of cardiovascular disease, and detection of pregnancy and ovulation.
Get a Sample Copy of the Report@ https://www.theinsightpartners.com/sample/TIPHE100001381/
As per the study reported by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020, ~6 million people in the US visit physicians for the treatment of urinary tract infection (UTIs) every year. Women are at a greater risk of developing UTIs than men. According to a study published in the International Journal of Environmental Research and Public Health in 2019, patients with existing chronic conditions, such as diabetes mellitus (DM), are at a greater risk of acquiring UTIs. The demand for components required for urinalysis is rising due to the common occurrence of diabetes across the world, as the primary screening for diabetes involves urinalysis. As per the International Diabetes Federation (IDF), ~463 million adults (age 20–79 years) in the world were living with diabetes in 2019; this number is likely to rise to 700 million by 2045. According to the IDF, ~87.6 million adults of age 20–79 was living with diabetes in Southeast Asia in 2019, representing a regional prevalence of 8.8%, and ~56.7% of these diabetes cases were undiagnosed, this shows there is potential for market development of urinalysis. Moreover, according to a study published by the National Kidney Foundation in 2020, ~35.0% of the diabetic population above age 20 would develop chronic kidney diseases over the period. An ongoing surge in the prevalence of prostate and bladder cancer raises a strong therapeutic imperative for the implementation of highly effective diagnostics.
COVID-19 has presented the most significant global health emergency till date. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of instruments, consumables, and reagents. The urinalysis market witnessed a shortfall at the beginning of the COVID-19 crisis due to disruption in supply chain and demand due to the lockdown announced by most European countries. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement.
Segmentation of Urinalysis Market:
Based on product, the Urinalysis market is segmented into consumables and instruments. The consumables segment would account for the largest market share in 2021, and the same segment is anticipated to register the highest CAGR during the forecast period.
Based on test type, the Urinalysis market is segmented into pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. The biochemical urinalysis segment would hold the largest share of the market in 2021, and it is estimated to register the highest CAGR in the market during 2021–2028. The growth of the biochemical urinalysis segment is attributed to the increased adoption of biochemical urinalysis.
Based on application, the Urinalysis market is segmented into disease screening and pregnancy, and fertility. The disease screening segment would account for the largest market share in 2021. The market for this segment is estimated to grow at the highest CAGR from 2021 to 2028.
Based on end user, the Urinalysis market is segmented into hospitals and clinics, diagnostic laboratories, home care settings, and research laboratories and institutes. The hospitals and clinics segment would hold the largest share of the market in 2021, while the diagnostic laboratories segment is estimated to register the highest CAGR in the market during the forecast period.
About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as healthcare, media, and telecommunication.
Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused on market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, type, end users, etc., which helps our clients to gain a deeper analytical understanding of various research topics.
If you have any queries about this report or would like further information, please contact us:
North America: +1 646 491 9876
Asia Pacific: +91 20 6727 8686
Email: [email protected]